Elsewhere: [math people] [google] [google scholar]

- Nonparametric inference for immune response thresholds of risk in vaccine studies. The Annals of Applied Statistics 2019. 13:1147-1165 .
- Generalized semiparametric varying-coefficient model for longitudinal data with applications to adaptive treatment randomizations. Biometrics 2017. 73:441-451 .
- Model-robust inference for continuous threshold regression models. Biometrics 2017. 73:452-462 .
- Power/sample size calculations for assessing correlates of risk in clinical efficacy trials. Statistics in Medicine 2016. 35:3745-3759 .
- Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints. Statistics in Medicine 2015. 34:381-395 .
- Inferences on relative failure rates in stratified mark-specific proportional hazards models with missing marks, with application to human immunodeficiency virus vaccine efficacy trials. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2015. 64:49-73 .
- Comparing and combining biomarkers as principle surrogates for time-to-event clinical endpoints. Statistics in Medicine 2015. 34:381-395 .
- Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials. Statistics in Medicine 2014. 33:901-917 .
- Nonparametric Bounds and Sensitivity Analysis of Treatment Effects. Statistical Science 2014. 29:596-618 .
- Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials. Biometrics 2013. 69:301-309 .
- Quantile regression for competing risks data with missing cause of failure. Statistica Sinica 2012. 22:703-728 .
- Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks. Scandinavian Journal of Statistics 2012. 39:34-52 .
- Assessing Treatment-Selection Markers using a Potential Outcomes Framework. Biometrics 2012. 68:687-696 .
- Rejoinder to “A Note on Two-Sample Tests for Comparing Intra-Individual Genetic Sequence Diversity Between Populations”. Biometrics 2012. 68:- .
- Comparing Biomarkers as Principal Surrogate Endpoints. Biometrics 2011. 67:1442-1451 .
- Sensitivity Analyses Comparing Time-to-Event Outcomes Only Existing in a Subset Selected Postrandomization and Relaxing Monotonicity. Biometrics 2011. 67:1100-1110 .
- A sequential phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens. Statistical Communications in Infectious Diseases 2011. 3:NA-NA .
- Design of Observational Studies edited by P. R. Rosenbaum. Biometrics 2010. 66:994-995 .
- Increasing the efficiency of prevention trials by incorporating baseline covariates. Statistical Communications in Infectious Diseases 2010. 2:NA-NA .
- Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts. Statistics in Medicine 2010. 29:1061-1071 .
- Assessing Vaccine Effects in Repeated Low-Dose Challenge Experiments. Biometrics 2009. 65:1223-1232 .
- Proportional hazards models with continuous marks. The Annals of Statistics 2009. 37:394-426 .
- Reply to comment on ``Evaluating a surrogate endpoint at three level, with application to vaccine development'' (2008V27 p4758-4778). Statistics in Medicine 2009. 28:716-719 .
- Simultaneous Evaluation of the Magnitude and Breadth of a Left- and Right-Censored Multivariate Response, With Application to HIV Vaccine Development. Statistics in Biopharmaceutical Research 2009. 1:81-91 .
- Response to Andrew Dunning's comment on ‘Evaluating a surrogate endpoint at three levels, with application to vaccine development’. Statistics in Medicine 2009. 28:716-719 .
- Evaluating Candidate Principal Surrogate Endpoints. Biometrics 2008. 64:1146-1154 .
- Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model. The Annals of Applied Statistics 2008. 2:386-407 .
- Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the cox model. The Annals of Applied Statistics 2008. 2:386-407 .
- Genome Scanning Tests for Comparing Amino Acid Sequences Between Groups. Biometrics 2008. 64:198-207 .
- Evaluating a surrogate endpoint at three levels, with application to vaccine development. Statistics in Medicine 2008. 27:4758-4778 .
- Comment on ``Evaluating a surrogate endpoint at three levels, with application to vaccine development'' (2008V27 p4758-4778). Statistics in Medicine 2008. 27:6268-6270 .
- Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization. Journal of the American Statistical Association 2007. 102:573-582 .
- Semiparametric estimation of treatment effects given base-line covariates on an outcome measured after a post-randomization event occurs. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 2007. 69:879-901 .
- Eliciting a Counterfactual Sensitivity Parameter. The American Statistician 2007. 61:56-63 .
- Nonparametric Estimation of the Joint Distribution of a Survival Time Subject to Interval Censoring and a Continuous Mark Variable. Biometrics 2007. 63:372-380 .
- A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial. Biometrics 2006. 62:893-900 .
- Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials. Biometrics 2006. 62:332-342 .
- Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation. Biostatistics (Oxford) 2005. 6:374-394 .
- A modified false discovery rate multiple-comparisons procedure for discrete data, applied to human immunodeficiency virus genetics. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2005. 54:143-158 .
- Two-sample tests for comparing intra-individual genetic sequence diversity between populations. Biometrics 2005. 61:106-117 .
- Endpoints in vaccine trials. Statistical Methods in Medical Research 2004. 13:89-114 .
- Tests for comparing mark-specific hazards and cumulative incidence functions. Lifetime Data Analysis 2004. 10:5-28 .
- Goodness-of-fit tests for semiparametric biased sampling models. Journal of Statistical Planning and Inference 2004. 118:51-81 .
- Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics 2003. 59:531-541 .
- Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Statistics in Medicine 2003. 22:573-593 .
- Simultaneous inferences on the contrast of two hazard functions with censored observations. Biometrics 2002. 58:773-780 .
- Flexible weighted log-rank tests optimal for detecting early and/or late survival differences. Biometrics 2002. 58:997-1004 .
- Omnibus tests for comparison of competing risks with adjustment for covariate effects. Biometrics 2001. 57:818-828 .
- Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy. Statistics in Medicine 2001. 20:263-279 .
- Large sample theory of maximum likelihood estimates in semiparametric biased sampling models. The Annals of Statistics 2000. 28:151-194 .
- Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection. Statistics in Medicine 2000. 19:3065-3086 .
- Large sample theory of maximum likelihood estimates in semiparametric biased sampling models. The Annals of Statistics 2000. 28:151-194 .
- Some statistical issues in the design of HIV-1 vaccine and treatment trials. Statistical Methods in Medical Research 2000. 9:207-229 .
- Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials. Biometrika 1999. 86:27-43 .
- Semiparametric efficient estimation in the generalized odds-rate class of regression models for right-censored time-to-event data. Lifetime Data Analysis 1998. 4:355-391 .
- Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Biometrics 1998. 54:799-814 .